Krystal Biotech (KRYS) Return on Capital Employed (2017 - 2026)
Krystal Biotech (KRYS) reported Return on Capital Employed of 14.21% for Q1 2026, up 318.0% on a YoY basis from 3.4% in Q1 2025, and up 4.33% sequentially from 13.62% in Q4 2025.
Krystal Biotech (KRYS) Return on Capital Employed (2017 - 2026) Analysis & Trends
Krystal Biotech (KRYS) has 10 years of Return on Capital Employed data on file, last reported at 14.21% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 318.0% year-over-year to 14.21%; the trailing twelve-month figure through Mar 2026 stood at 14.21% (up 318.0% YoY), and the FY2025 full-year result was 14.77%, up 690.0% from the prior year.
- Return on Capital Employed advanced to 14.21% in Q1 2026, from 13.62% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.42% in Q3 2025 to a low of 28.19% in Q1 2023.
- A 5-year average of 6.62% and a median of 8.56% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 1365 bps in 2022 and soared 2401 bps in 2024, its largest moves.
- Tracing KRYS's Return on Capital Employed over 5 years: stood at 26.96% in 2022, then soared by 47 bps to 14.21% in 2023, then surged by 150 bps to 7.17% in 2024, then surged by 90 bps to 13.62% in 2025, then increased by 4 bps to 14.21% in 2026.
- Business Quant data shows KRYS's Return on Capital Employed at 14.21% in Q1 2026, 13.62% in Q4 2025, and 14.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Krystal Biotech | 9.84 Bn | 9.02 Bn | 110.08 Mn | 14.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.21% |
| Dec 31, 2025 | 13.62% |
| Sep 30, 2025 | 14.42% |
| Jun 30, 2025 | 13.67% |
| Mar 31, 2025 | 11.02% |
| Dec 31, 2024 | 7.17% |
| Sep 30, 2024 | 3.21% |
| Jun 30, 2024 | -2.56% |
| Mar 31, 2024 | -8.56% |
| Dec 31, 2023 | -14.21% |
| Sep 30, 2023 | -20.81% |
| Jun 30, 2023 | -26.21% |
| Mar 31, 2023 | -28.19% |
| Dec 31, 2022 | -26.96% |
| Sep 30, 2022 | -23.59% |
| Jun 30, 2022 | -20.27% |
| Mar 31, 2022 | -18.56% |
| Dec 31, 2021 | -13.31% |
| Sep 30, 2021 | -13.81% |
| Jun 30, 2021 | -11.96% |